欧洲药品管理局（EMA）人用药品委员会（CHMP）已对Joenja（Leniolisib）发出积极意见，建议其在特殊情况下授予上市许可。这一关键进展为特定患者群体的治疗带来了新的希望。
欧洲药品管理局（EMA）人用药品委员会（CHMP）已对Joenja（Leniolisib）发出积极意见，建议其在特殊情况下授予上市许可。这一关键进展为特定患者群体的治疗带来了新的希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.